Table 5 Enriched pathways from GSEA on attributed saliency scores.
From: Drug discovery and mechanism prediction with explainable graph neural networks
Drug | Term | ES | NES |
|---|---|---|---|
Afatinib | HALLMARK_KRAS_SIGNALING_UP | 356.8 | 0.7 |
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | 350.5 | 0.68 | |
HALLMARK_INFLAMMATORY_RESPONSE | 316.08 | 0.62 | |
HALLMARK_ALLOGRAFT_REJECTION | 268.76 | 0.52 | |
HALLMARK_APICAL_JUNCTION | 268.5 | 0.52 | |
Imatinib | HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | 343.83 | 0.73 |
HALLMARK_KRAS_SIGNALING_UP | 298.37 | 0.63 | |
HALLMARK_APICAL_JUNCTION | 289.58 | 0.62 | |
HALLMARK_MYOGENESIS | 282.84 | 0.6 | |
HALLMARK_TNFA_SIGNALING_VIA_NFKB | 280.9 | 0.6 | |
Sunitinib | HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | 345.81 | 0.73 |
HALLMARK_KRAS_SIGNALING_UP | 307.34 | 0.65 | |
HALLMARK_APICAL_JUNCTION | 290.69 | 0.61 | |
HALLMARK_TNFA_SIGNALING_VIA_NFKB | 277.54 | 0.59 | |
HALLMARK_UV_RESPONSE_DN | 264.91 | 0.56 |
